Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 8Neoplasms 4Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Carcinoid Tumor 3Adenoma, Islet Cell 3Adenocarcinoma, Follicular 3Paraganglioma 2Carcinoma, Medullary 2Carcinoma 2Adenoma 2Pheochromocytoma 1Pancreatic Neuroendocrine Tumour Metastatic 1Pancreatic Neuroendocrine Tumors 1Pancreatic Diseases 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasms, Nerve Tissue 1Neoplasms, Glandular and Epithelial 1Neoplasms, Germ Cell and Embryonal 1Neoplasms by Site 1Neoplasms by Histologic Type 1Metastatic Digestive System Neuroendocrine Tumor G1 1Gastro-enteropancreatic neuroendocrine tumor 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Digestive System Neoplasms 1Digestive System Diseases 1

Interventions

Sunitinib 1Robotic Surgical Procedures 1Laparoscopy 1Everolimus 1Conversion to Open Surgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neuroendocrine Tumors × Sunitinib × Endocrine × Clear all
NCT02282059 2024-06-20

The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors

Pfizer

Completed
100 enrolled 13 charts
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡